Ramiro S, Landewé RBM, van der Heijde D, et al. - This study was undertaken to evaluate if following a treat-to-target (T2T)-strategy in daily clinical practice leads to more individuals with rheumatoid arthritis (RA) meeting the remission target. Researchers examined RA individuals from 10 countries starting/changing conventional synthetic or biological disease-modifying anti-rheumatic drugs for disease activity every 3 months for 2 years (RA BIODAM (BIOmarkers of joint DAMage) cohort). This study included 4,356 visits including a total of 571 individuals (mean (SD) age: 56 (13) years, 78% female). It was demonstrated that correct application of a T2T-strategy (especially sustained T2T) in individuals with RA leads to higher rates of remission in daily clinical practice.